the antitumor activity against bladder tumor. And, other studies reported that IL-15 plays an important role in neutrophil migration during inflammation. In the present study, we constructed a recombinant BCG expressing the fusion protein of IL-15 (BCG-IL-15) and examined the efficacy of BCG-IL-15 in providing protection against bladder cancer.
INTRODUCTION AND OBJECTIVES: The mechanisms of bladder cancer metastasis are incompletely understood. To this end, we performed gene expression profiling comparing matched primary tumors to lymph node metastases. LimD2, a gene previously implicated in papillary thyroid cancer metastasis through modulation of integrin signaling, was found to be upregulated in bladder cancer lymph node (LN) metastases. We sought to further characterize the relationship of LimD2 and bladder cancer metastasis. METHODS: RNA from both primary tumor and lymph node metastases from 29 patients with pN+ disease at cystectomy was collected and used for gene expression profiling. Immunohistochemistry was performed to confirm the results at the cellular and protein level. LimD2 expression in primary tumors was evaluated in silico in several cohorts including the TCGA. LimD2 expression in urothelial cancer cell lines of both basal and luminal molecular phenotypes was evaluated by western blot. Constructs resulting in LimD2 overexpression and knockdown were stably transfected in urothelial cancer cell lines which will then be used for in vitro and in vivo metastatic assays.
RESULTS: In patient-matched cystectomy/lymphadenectomy samples, LimD2 RNA expression was 4.7 fold higher in lymph node metastases compared to primary tumors (paired t-test p< 0.0001). These results were confirmed at the cellular and protein level by immunohistochemistry in a subset of the same patient samples. In silico analysis in several cohorts showed that LimD2 expression in the primary tumor was higher in basal and TCGA cluster IV molecular phenotypes, compared with luminal phenotypes (p¼0.039, p¼0.002 respectively). This pattern was confirmed in urothelial cancer cell lines, as cells with a basal phenotype (T24, J82, TCCSUP) showed much higher expression of LimD2 protein compared with luminal phenotype cells (UC14, RT112, UC6).
CONCLUSIONS: LimD2 expression is upregulated during bladder cancer metastasis and is correlated with aggressive basal molecular phenotypes. Given its ability to modulate integrin signaling, LimD2 is mechanistically heavily implicated in bladder cancer metastasis. METHODS: Full-length lncRNA MEG3 and its controls were stably transfected into human bladder cancer cell lines, T24T and UMUC3, that were originally derived from high-grade, muscle-invasive bladder cancers. The effects of MEG3 expression on bladder cancer cells including proliferation and invasion were accessed. RNA immunoprecipitation was used to identify the binding between MEG3 and miR-27a. RNA binding-site point-mutation experiments and luciferase reporter assay were used to study 3'-UTR activity of PHLPP2 and the promoter activity of c-Myc, respectively.
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RESULTS: We found that stable expression of MEG3, but not its controls, in T24T and UMUC3 cells strongly inhibited human bladder cancer cell proliferation and invasion. MEG3 exerted these anti-tumor effects by binding specifically to microRNA, miR-27a, and competing its binding for the mRNA of PHLPP2, a tumor suppressor that inhibits the AKT pathway. By so doing, MEG3 markedly reduced the activity of miR-27a and in turn increased the protein translation of PHLPP2. As a consequence, the upregulated PHLPP2 decreased c-Jun phosphorylation at Ser63/73, and inhibited c-Myc transcription, thus reducing the invasiveness of bladder cancer cells.
CONCLUSIONS: We demonstrate for the first time that MEG3, transcribed from a gene locus with recurrent epigenetic silencing in e1314 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Tuesday, May 16, 2017 
